Editorial issue 263

This 263th issue of NDT-Edu starts with 5 very interesting papers.
In the first one, Said S.M. et al report in the januari issue of Kidney Int on the "Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis". Interestingly, this newly described type of amyloidosis mostly affects elderly hispnanics, and may in some cases not present with proteinuria.
In the second paper, Zaidan M. et al , again in KI, report on the "Increased risk of solid renal tumors in lithium-treated patients". Again an important information for nephrologists following lithium –treated patients with CKD.
In the third one, in KI too, Hwang D-Y. et al  publish a large series of detailed genetic analysis of  congenital anomalies of the kidney and urinary tract (CAKUT).
In the fourth one, in Nephrol Dial Transplant. (February 2014), Cozzolino M. et al in report the results of the IMPACT-SHPT study ,comparing  Paracalcitol- or cinacalcet-centred therapy in patients with secondary hyperparathyroidism receiving hemodialysis.
Finally, in a JCI paper, Zhou B. et al report that Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. These results are in line with some findings of the TREAT trial and remind nephrologists of the fact that Erythropoiesis–stimulating agents should be used with great caution in patients with a history of cancer.

Two CME lectures from ERA-EDTA Congress are also on the menu of this NDT-Edu.    
In the first one, Prof. T. Alp Ikizler (Nashville, TN, USA) provides an overview of biomarkers under the title "Are biomarkers so perfect?"
In the second one,  Prof. Wim Van Biesen (Ghent, Belgium) discusses the respective roles of Biomarkers versus clinical assessment in AKI.

Enjoy NDt-Edu

Prof. Michel Jadoul
Editor-in-Chief NDT-Educational